Baxter International Inc. (BIT:1BAX)
Italy
· Delayed Price · Currency is EUR 26.36
+0.20 (0.75%)
At close: Jun 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Chronic Therapies | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chronic Therapies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Nutrition | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Nutrition Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Surgery | 1.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Surgery Growth | 3.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Therapies | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Therapies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Patient Support Systems | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Patient Support Systems Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Front Line Care | 1.15B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Front Line Care Growth | -2.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables and Anesthesia | 1.38B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables and Anesthesia Growth | 0.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Compounding | 1.03B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Compounding Growth | 10.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Post-Q2 2023 Reporting) | 129.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Post-Q2 2023 Reporting) Growth | 76.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Medical Products & Therapies Operating Income | 967.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Products & Therapies Operating Income Growth | -3.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Operating Income | 494.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Operating Income Growth | 12.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Operating Income | 298.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Operating Income Growth | -23.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kidney Care Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income | 23.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income Growth | 53.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| United States Revenue | 6.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue Growth | 3.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue | 1.84B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue Growth | -1.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue | 3.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue Growth | 4.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|